

COPY OF PAPERS
ORIGINALLY FILED

1614
IDS #3
3/01/02
PATENT
ATTORNEY DOCKET NO. 50211/015003

Certificate of Mailing: Date of Deposit: 2/5/02

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Mary Jane D. Palma

Printed name of person mailing correspondence

Mary Jane D. Palma

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 26 2002

Applicant: Keith Schappert

Art Unit: 1644

Serial No.: 10/017,828

Examiner: Not yet assigned

Filed: December 7, 2001

Customer No.: 21559

Title: METHODS FOR TREATING OR IDENTIFYING A SUBJECT AT RISK FOR A NEUROLOGICAL DISEASE BY DETERMINING THE PRESENCE OF A VARIANT GPIIIa and/or GPIIb ALLELE

TECH CENTER 1600/2900

Assistant Commissioner For Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449. Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/409,648, filed on October 1, 1999. The references listed on the attached PTO 1449 were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

If there are any charges, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

COPY OF PAPERS
ORIGINALLY FILED

Date:

Kristina Bieker-Brady

Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

RECEIVED

FEB 26 2002

TECH CENTER 1600/2900




21559

PATENT TRADEMARK OFFICE

C:\50211.015003 PTO 1449 IDS.wpd

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



**COPY OF PAPER
ORIGINALLY FILED**

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No.	50211/015003 10/017,828
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Filing Date	Keith Schappert December 7, 2001
(37 CFR §1.98(b))		Group IDS Filed	1644 a/s/c Customer No.: 21559

RECEIVED

FEB 26 2002

TECH CENTER 1600/290C

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,955,266	09/21/99	Bray et al.			
	5,935,781	08/10/99	Poirier			
	5,767,248	06/16/98	Roses et al.			
	5,652,357	07/29/97	Newman et al.			
	5,716,828	02/10/98	Roses et al.			
	5,391,714	02/21/95	Newman et al.			
	5,508,167	04/16/96	Roses et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/66072	23 12 1999	PCT			
	WO 99/15159	01 04 1999	PCT			
	WO 99/14367	25 03 1999	PCT			
	WO 98/27227	25 06 1998	PCT			
	WO 98/27226	25 06 1998	PCT			
	WO 96/03656	08 02 1996	PCT			
	WO 96/02670	01 02 1996	PCT			
	WO 95/29257	02 11 1995	PCT			
	WO 94/09155	28 04 1994	PCT			
	WO 91/08306	13 06 1991	PCT			
	EP 0200362	10 12 1986	Europe			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50211/015003 Serial No. 10/017,828 Applicant Keith Schappert Filing Date December 7, 2001 Group 1644 IDS Filed 2/5/02 Customer No.: 21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
(37 CFR §1.98(b))		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Basani et al., "Glanzmann Thrombasthenia Due to a Two Amino Acid Deletion in the Fourth Calcium-Binding Domain of α_{IIb} : Demonstration of the Importance of Calcium-Binding Domains in the conformation of $\alpha_{IIb}\beta_3$," <i>Blood</i> 88:167-173, 1996.	
	Bray et al., "Physical Linkage of the Genes for Platelet Membrane Glycoproteins IIb and IIIa," <i>Proc. Natl. Acad. Sci.</i> 85:8683-8687, 1988.	
	Bray et al., "Platelet Glycoprotein IIb. Chromosomal Localization and Tissue Expression," <i>J. Clin. Invest.</i> 80:1812-1817, 1987.	
	Brindle et al., "Analysis of the Butyrylcholinesterase Gene and nearby Chromosome 3 Markers in Alzheimer Disease," <i>Hum. Mol. Genetics</i> , 7:933-935, 1998.	
	Cong et al., "Assignment of Human Platelet GP2 (GP IIb) Gene to Chromosome 17, Region q21.1-q21.3," <i>Hum. Genet.</i> 80:389-392, 1988	
	Corder et al., "Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families," <i>Science</i> 261:921-923, 1993.	
	Cummings et al., "Alzheimer's Disease. Etiologies, Pathophysiology, Cognitive Reserve, and Treatment Opportunities," <i>Neurology</i> 51(Supp.1):S2-S17, 1998.	
	Galasko et al., "Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias," <i>Arch. Neurol.</i> 51:888-895, 1994.	
	Gustincich et al., "A Fast Method for High-Quality Genomic DNA Extraction from Whole Human Blood," <i>Biotechniques</i> 11:298-300, 1991.	
	Lyman et al., "Polymorphism of Human Platelet Membrane Glycoprotein IIb Associated with the Bak ^a /Bak ^b Alloantigen System," <i>Blood</i> 75(12):2343-2348, 1990.	
	Newman et al., "The Molecular Genetic basis of Glanzmann Thrombasthenia in the Iraqi-Jewish and Arab Populations in Israel," <i>Proc. Natl. Acad. Sci. USA</i> 88:3160-3164, 1991.	
	Newman et al., "The Human Platelet Alloantigens, PI ^{A1} and PI ^{A2} , are Associated with a Leucine ³³ /Proline ³³ Amino Acid Polymorphism in Membrane Glycoprotein IIIa, and are Distinguishable by DNA Typing," <i>J. Clin. Invest.</i> 83:1778-1781, 1989.	
	Noguchi et al., "Apolipoprotein E Genotype and Alzheimer's Disease," <i>Lancet</i> (letter) 342:737, 1993.	
EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50211/015003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/017,828
(37 CFR §1.98(b))		Applicant Keith Schappert
		Filing Date December 7, 2001
		Group 1644
		IDS Filed 2/5/03
		Customer No.: 21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Payami et al., "Apolipoprotein E Genotype and Alzheimer's Disease," <i>Lancet</i> (letter) 342:738, 1993.	
	Poirier et al., "Apolipoprotein E Phenotype and Alzheimer's Disease," <i>Lancet</i> 342:697-699, 1993.	
	Poncz et al., "Structure of the Platelet Membrane Glycoprotein IIb," <i>J. Biol. Chem.</i> 262:8476-8482, 1987.	
	Richard et al., "APOE Genotyping and Response to Drug Treatment in Alzheimer's Disease," <i>Lancet</i> 349:539, 1997.	
	Singleton et al., "No Association between the K Variant of the Butyrylcholinesterase Gene and Pathologically Confirmed Alzheimer's Disease," <i>Hum. Molecular Genetics</i> 7:937-939, 1998.	
	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era" <i>Trends in Biotechnology</i> 18:34-39, Jan. 2000	
	Uzan et al., "cDNA Clones for Human Platelet GPIIb Corresponding to mRNA from Megakaryocytes and HEL Cells. Evidence for an Extensive Homology to Other Arg-Gly-Asp Adhesion Receptors," <i>Eur. J. Biochem.</i> 171:87-93, 1988	
	Weiss et al., "A Monoclonal Antibody (SZ21) Specific for Platelet GPIIIa Distinguishes PI ^{A1} from PI ^{A2} ," <i>Tissue Antigens</i> 46:374-381, 1995.	
	Zimrin et al., "Structure of Platelet Glycoprotein IIIa," <i>J. Clin. Invest.</i> 81:1470-1475, 1988.	
EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		